NovoCure (NVCR) Short-term Investments (2014 - 2026)

NovoCure has disclosed Short-term Investments across 13 years of filings, most recently posting $344.5 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $344.5 million, down 57.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $344.5 million (down 57.04% YoY), and the FY2025 annual result was $9.8 million, down 98.76% from the prior year.
• Short-term Investments came in at $344.5 million for Q1 2026 at NovoCure, up from $9.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $854.1 million in Q4 2022 to a low of $231000.0 in Q3 2022.
• The 5-year median for Short-term Investments is $344.5 million (2026), against an average of $354.5 million.
• Peak annual rise in Short-term Investments reached 331669.7% in 2023, while the deepest fall reached 99.91% in 2023.
• NovoCure's Short-term Investments stood at $854.1 million in 2022, then retreated by 21.58% to $669.8 million in 2023, then rose by 18.86% to $796.1 million in 2024, then slumped by 98.76% to $9.8 million in 2025, then soared by 3400.07% to $344.5 million in 2026.
• The last three Short-term Investments figures came in at $344.5 million (Q1 2026), $9.8 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.